Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
Veradermics, Incorporated (MANE)
Company Research
Source: Business Wire
This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studiesTopline data from initial '302' trial anticipated in the first half of 2026; '304' confirmatory study topline data anticipated in the second half of 2026VDPHL01, if approved, has the potential to be the first and only non-hormonal oral FDA approved treatment for men and women with pattern hair loss, a condition affecting an estimated 50 million men and 30 million women in the United States NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announc
Show less
Read more
Impact Snapshot
Event Time:
MANE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MANE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MANE alerts
High impacting Veradermics, Incorporated news events
Weekly update
A roundup of the hottest topics
MANE
News
- MANE (NYSE:MANE) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MANE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to a "hMarketBeat
- Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public OfferingBusiness Wire
- Veradermics Announces Pricing of Upsized Initial Public OfferingBusiness Wire
MANE
Sec Filings
- 2/12/26 - Form SCHEDULE
- 2/12/26 - Form SCHEDULE
- 2/11/26 - Form SCHEDULE
- MANE's page on the SEC website